Jonathan Kell

3.6k total citations · 2 hit papers
57 papers, 2.5k citations indexed

About

Jonathan Kell is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Molecular Biology. According to data from OpenAlex, Jonathan Kell has authored 57 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Hematology, 23 papers in Public Health, Environmental and Occupational Health and 19 papers in Molecular Biology. Recurrent topics in Jonathan Kell's work include Acute Myeloid Leukemia Research (37 papers), Acute Lymphoblastic Leukemia research (17 papers) and Retinoids in leukemia and cellular processes (12 papers). Jonathan Kell is often cited by papers focused on Acute Myeloid Leukemia Research (37 papers), Acute Lymphoblastic Leukemia research (17 papers) and Retinoids in leukemia and cellular processes (12 papers). Jonathan Kell collaborates with scholars based in United Kingdom, United States and Denmark. Jonathan Kell's co-authors include Alan K. Burnett, Nigel H. Russell, Robert K. Hills, Keith Wheatley, Lars Kjeldsen, Donald Milligan, Ann Hunter, Richard E. Clark, Anthony H. Goldstone and John A. Liu Yin and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Jonathan Kell

56 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial

2010 490 citations Alan K. Burnett, Robert K. Hills et al. Journal of Clinical Oncology profile →
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial

2015 346 citations Alan K. Burnett, Nigel H. Russell et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Jonathan Kell

Since Specialization

Citations

This map shows the geographic impact of Jonathan Kell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Kell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Kell more than expected).

Fields of papers citing papers by Jonathan Kell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan Kell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Kell. The network helps show where Jonathan Kell may publish in the future.

Co-authorship network of co-authors of Jonathan Kell

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan Kell. A scholar is included among the top collaborators of Jonathan Kell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan Kell. Jonathan Kell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Management of older patients with frailty and acute myeloid leukaemia: A British Society for Haematology good practice paper 2022 ·British Journal of Haematology ·Mike Dennis, Mhairi Copland, Harpreet Kaur, Jonathan Kell, Emmanouil Nikolousis, Priyanka Mehta, (unknown), Victoria Potter, Kavita Raj, Ian Thomas, Andrew J. Wilson	1
2	British Society for Haematology guidelines for the management of adult myelodysplastic syndromes 2021 ·British Journal of Haematology ·Sally Killick, Wendy Ingram, Dominic Culligan, Helen Enright, Jonathan Kell, Elspeth Payne, Pramila Krishnamurthy, Austin Kulasekararaj, Manoj Raghavan, Simon Stanworth, (unknown), Ghulam Mufti, Lynn Quek, Catherine Cargo, Gail Jones, (unknown), Alex Sternberg, Daniel H. Wiseman, David Bowen	14
3	Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses 2020 ·Journal of Clinical Oncology ·Alan K. Burnett, Nigel H. Russell, Robert K. Hills, Steven Knapper, Sylvie Freeman, Brian J.P. Huntly, Richard E. Clark, Ian F. Thomas, Lars Kjeldsen, Mary Frances McMullin, Mark W. Drummond, Jonathan Kell, Ruth Spearing	19
4	Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study 2020 ·Frontiers in Pharmacology ·(unknown), Esther N. Oliva, Tatyana Ionova, (unknown), Jonathan Kell, Adele K. Fielding, (unknown), Μαρίνα Καρακάντζα, Saad Al‐Ismail, Graham P. Collins, Stewart McConnell, (unknown), Magda Al-Obaidi, Metod Oblak, Sam Salek	12
5	Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PRO 2020 ·Frontiers in Pharmacology ·(unknown), Esther N. Oliva, Tatyana Ionova, (unknown), Jonathan Kell, Adele K. Fielding, (unknown), Μαρίνα Καρακάντζα, Saad Al‐Ismail, Graham P. Collins, Stewart McConnell, (unknown), Magda Al-Obaidi, Metod Oblak, Sam Salek	5
6	PRO146 HEALTH-RELATED QUALITY OF LIFE AND PRODUCTIVITY/ACTIVITY IMPAIRMENT IN PATIENTS WITH TRANSFUSION DEPENDENT B-THALASSAEMIA IN THE UK NHS: DATA FROM A UK MULTICENTRE OBSERVATIONAL STUDY 2019 ·Value in Health ·Kate Ryan, Shivan Pancham, Paul Telfer, Farrukh Shah, Jonathan Kell, (unknown), Robert Wynn, Mark Velangi, Elizabeth Chalmers, (unknown), Clark Paramore, (unknown)	1
7	A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia 2016 ·Leukemia ·(unknown), Alan K. Burnett, Nigel H. Russell, Robert K. Hills, Jonathan Kell, Olav Wendelboe Nielsen, Mike Dennis, Paul Cahalin, Chris Pocock, Sahra Ali, Sarah S. Burns, Sylvie Freeman, D Milligan, Richard E. Clark	17
8	Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 Trial 2016 ·Haematologica ·Alan K. Burnett, Jamie Cavenagh, Nigel H. Russell, Robert K. Hills, Jonathan Kell, Gail Jones, Olav Wendelboe Nielsen, Asim Khwaja, Ian Thomas, Richard E. Clark, (unknown)	56
9	Considerations and challenges for patients with refractory and relapsed acute myeloid leukaemia 2016 ·Leukemia Research ·Jonathan Kell	12
10	Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial breakdown → 2015 ·The Lancet Oncology ·Alan K. Burnett, Nigel H. Russell, Robert K. Hills, David Bowen, Jonathan Kell, Steven Knapper, Yvonne G Morgan, (unknown), Angela Grech, Gail Jones, Asim Khwaja, Lone S. Friis, Mary Frances McMullin, Ann Hunter, Richard E. Clark, David Grimwade	346
11	Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial 2012 ·Leukemia ·Alan K. Burnett, Robert K. Hills, David Grimwade, Jelena Jovanović, J Craig, M. F. McMullin, Jonathan Kell, Keith Wheatley, J. A. Liu Yin, Ann Hunter, Don Milligan, Nigel H. Russell	53
12	Prophylactic treatment for cytosine arabinoside-induced keratoconjunctivitis 2011 ·International Ophthalmology ·(unknown), William J. Sheehan, (unknown), C Lane, Jonathan Kell	1
13	The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome 2011 ·Leukemia ·Alan K. Burnett, Robert K. Hills, Ann Hunter, D Milligan, Jonathan Kell, Keith Wheatley, J. A. Liu Yin, (unknown), Paul Cahalin, J Craig, David Bowen, Nigel H. Russell	35
14	Clinical impact of enhanced diagnosis of invasive fungal disease in high-risk haematology and stem cell transplant patients 2008 ·Journal of Clinical Pathology ·Rosemary A. Barnes, P. Lewis White, Ceri Bygrave, Neil D. Evans, Brendan Healy, Jonathan Kell	71
15	Treatment of Relapsed Acute Myeloid Leukaemia 2006 ·Reviews on Recent Clinical Trials ·Jonathan Kell	23
16	Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): An overview from the research on adverse drug events and reports (RADAR) project 2006 ·Leukemia Research ·June M. McKoy, Cara Angelotta, Charles L. Bennett, Martin S. Tallman, Martha Wadleigh, Andrew M. Evens, Timothy M. Kuzel, Steve Trifilio, Dennis W. Raisch, Jonathan Kell, Daniel J. DeAngelo, Francis J. Giles	129
17	Invasive aspergillosis localised to the colon presenting as toxic megacolon 2006 ·European Journal Of Haematology ·(unknown), Jonathan Kell, (unknown), Claire O’Brien, Suman Kundu, J. Rees, (unknown)	26
18	Retinoid‐induced apoptosis in B‐cell chronic lymphocytic leukaemia cells is mediated through caspase‐3 activation and is independent of p53, the retinoic acid receptor, and differentiation 2002 ·European Journal Of Haematology ·Chris Pepper, (unknown), Alun Thomas, Timothy J. Hoy, Chris Fegan, Pratima Chowdary, Jonathan Kell, Paul Bentley	14
19	Acute myeloid leukemia: therapeutic indications 2000 ·Current Opinion in Hematology ·Alan K. Burnett, Jonathan Kell, Clare Rowntree	11
20	Oxford Advanced Learner's Dictionary on CD-ROM 1999 ·BioTechniques ·Jonathan Kell	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact